We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0AB6 market cap is 0. The company's latest EPS is EUR -0.5629 and P/E is -20.79.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 91k | 175k | 3.1M | 2.95M | 0 |
| Operating Income | -5.27M | -7.05M | -10.54M | -10.64M | -16.24M |
| Net Income | -5.37M | -7.15M | -11.58M | -10.77M | -15.76M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 5.98M | 69.18M | 63.44M | 61.86M | 47.61M |
| Total Liabilities | 16.17M | 10.12M | 15.39M | 6.82M | 8.79M |
| Total Equity | -10.19M | 59.06M | 48.06M | 55.05M | 38.82M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -4.56M | -4.57M | -11.25M | -13.15M | -12.73M |
| Investing | -1.23M | -633k | -3.08M | -1.24M | 9.65M |
| Financing | 3.31M | 69.4M | -62k | 7.84M | -188k |
| Market Cap | 0 |
| Price to Earnings Ratio | -20.79 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 10.85 |
| Price to Book Ratio | 8.44 |
| Dividend Yield | - |
| Shares Outstanding | 28M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Hyloris Pharmaceuticals Sa |
| Address |
boulevard patience et beaujonc liege, liege 4000 |
| Website | https://www.hyloris.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
